Episode
SS-31: The Peptide ‘Mitochondrial Shield’ That May Block Parkinson’s Damage at the Source
- Podcast
- The Energy Code
- Published
- Jun 5, 2026
- Duration seconds
- 873
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-energy-code-2136601/episodes/ss-31-the-peptide-mitochondrial-shield-that-may-block-parkinson-s-damage-at-the-source/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-energy-code-2136601/ss-31-the-peptide-mitochondrial-shield-that-may-block-parkinson-s-damage-at-the-source.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This is the first dedicated peptide deep dive of The Energy Code — and it starts with arguably the most mitochondrial-centric peptide on the board: SS-31 (Elamipretide). Dr. Mike breaks down a new paper showing how SS-31 may protect neurons in Parkinson’s disease by competing with alpha-synuclein at lipid membranes, slowing toxic aggregation, restoring mitochondrial respiration, and even reducing alpha-synuclein cellular entry. You’ll also hear a key caution: SS-31 appears highly protective at moderate doses, but too much may flip the benefit into harm, reinforcing the “dose makes the medicine” rule in mitochondrial pharmacology. (Educational content only, not medical advice.) - Article Discussed in Episode: Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function - Key Quotes From Dr. Mike: “The future of Parkinson’s therapy may not lie in cleaning up the mess, but rather in providing our neurons with a permanent molecular shield…” “SS-31 acts as a molecular shield protecting the brain’s energy supply…” “SS-31 acts as a molecular bouncer, physically evicting alpha-synuclein from lipid membranes…” “SS-31 substantially prolonged the lag phase of aggregation, essentially stalling the clock on protein buildup.” “These findings underscore the multifaceted protective role of SS-31 against mitochondrial dysfunction caused by alpha synuclein aggregation... SS-31 reversed this decline with a 10 micromolar dose…” - Key Points SS-31 is framed as a mitochondria-first peptide: “restore impaired mitochondrial function” is the headline. Parkinson’s pathology is presented as a cellular power failure inside dopaminergic neurons driven by alpha-synuclein toxicity. SS-31 may act like a “molecular bouncer” — outcompe…